Our therapy recommendation considers everything relevant to the patient’s therapy at the given time. It includes in-label and off-label treatments as well as information on clinical trials. The tumor profile of our comprehensive NGS-based diagnostics (germline and tumor) and pathological reports, such as relevant immunohistochemical results, are taken into account. Based on this information, we evaluate each case individually and list the most promising targeted therapies based on the latest literature. For the off-label therapies indicated, we provide clinical evidence in tabular form with detailed information on study data, study conditions, biomarkers, drugs, drug dosage, and outcomes. The list of ongoing clinical trials matching targeted drug or genetic tumor alterations will be limited to five countries.